Clinical Trial

Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 9, 2026 (before its estimated June 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study was a multicenter, randomized, open, single-dose, two-cycle, two-cross-dosing human bioequivalence trial designed to evaluate the bioequivalence of tested and reference preparations in breast cancer subjects.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-03; most recent amendment 2026-03-05.
Status change: Not Yet Recruiting → Recruiting 2025-04-08
Trial Details
NCT Number NCT06765590
Lead Sponsor Sichuan Huiyu Pharmaceutical Co., Ltd
Collaborators: The First Hospital of Jilin University, The First Affiliated Hospital of Bengbu Medical University, Chongqing Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Henan University of Science and Technology, Qianfoshan Hospital
Conditions Breast Cancer
Enrollment 24 participants
Start Date 2025-03-12
Primary Completion 2026-06-12 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-09